Policy | May 29, 2021
Shilpa Medicare Jadcherla facility gets GMP certification from Russia
The GMP certificate is valid for three years until April 2024.
The GMP certificate is valid for three years until April 2024.
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The commercial production in the SML was started in November 1989.
The audit has been concluded with no major observations
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
he inspection covering the sterile drug product filling and packaging line, quality systems and quality control laboratories concluded compliance with the principles and guidelines of Good Manufacturing Practice
Raichur site is the group’s largest API facility and part of a wider network of seven sites
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
Subscribe To Our Newsletter & Stay Updated
